Indeed, GSK864, a compound initially identified as a potent inhibitor of mutant IDH1 in AML [82], inhibits wild-type IDH1 activity, reduces GBM stem-like cell frequency and increases survival of tumor-bearing mice. The gene discussed is IDH1; the disease is acute myeloid leukemia.